Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial - 28/01/23

Guiqiang Wang ^a, 1

  These authors contributed equally to this work.

, Kexin Zhao ^b, 1

  These authors contributed equally to this work.

, Jun Han ^c, 1

  These authors contributed equally to this work.

, Zhongyu Hu ^d, 1

  These authors contributed equally to this work.

, Tianzuo Zhang ^b, Yanchao Wang ^b, Rui Shi ^b, Yanhua Li ^b, Qinqin Song ^c, Haijun Du ^c, Peng He ^d, Shuping Xu ^e, Xinjie Yang ^e, Yongpan Fu ^e, Yimin Cui ^{f, ⁎} , Liangzhi Xie ^{e, g, ⁎}

^a Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital; Department of Infectious Disease, Peking University International Hospital, Beijing, China 

^b Hebei Petro China Central Hospital, Langfang, China 

^c State Key Laboratory of Infectious, Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China 

^d National Institutes for Food and Drug Control, Beijing, China 

^e Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China 

^f Department of Pharmacy, Peking University First Hospital; Institute of Clinical Pharmacology, Peking University Beijing, China 

^g Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China 

^⁎Corresponding authors.

Le texte complet de cet article est disponible en PDF.